Skip Nav Destination
Issues
15 June 2009
-
Cover Image
Cover Image
Reactive stroma from prostate cancer and normal prostatic stroma was laser captured, RNAs were amplified and gene expression analyzed using expression microarrays. A total of 1141 genes were differentially expressed in reactive compared with normal stroma. The Human Protein Reference Database catalogue of over 35,000 known physical protein-protein interactions was queried to determine how the reactive stroma-associated genes relate to each other in terms of interactions between their associated proteins. A total of 292 interactions were visualized as a graphical network. A view of the central node is shown. For further details, please see Dakhova and colleagues on page 3979 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
CCR Translations
CCR Practice of Translational Oncology
Molecular Pathways
CCR Special Focus
Human Cancer Biology
GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer
Debby M.E.I. Hellebrekers; Marjolein H.F.M. Lentjes; Sandra M. van den Bosch; Veerle Melotte; Kim A.D. Wouters; Kathleen L.J. Daenen; Kim M. Smits; Yoshimitsu Akiyama; Yasuhito Yuasa; Silvia Sanduleanu; Carolina A.J. Khalid-de Bakker; Daisy Jonkers; Matty P. Weijenberg; Joost Louwagie; Wim van Criekinge; Beatriz Carvalho; Gerrit A. Meijer; Stephen B. Baylin; James G. Herman; Adriaan P. de Bruïne; Manon van Engeland
Locked Nucleic Acid In situ Hybridization Analysis of miR-21 Expression during Colorectal Cancer Development
Nobutake Yamamichi; Ryoichi Shimomura; Ken-ichi Inada; Kouhei Sakurai; Takeshi Haraguchi; Yuka Ozaki; Shuji Fujita; Taketoshi Mizutani; Chihiro Furukawa; Mitsuhiro Fujishiro; Masao Ichinose; Kazuya Shiogama; Yutaka Tsutsumi; Masao Omata; Hideo Iba
Cancer Therapy: Preclinical
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Robert J. Lutz; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Sonia Vallet; Samantha Pozzi; Loredana Santo; Giulia Perrone; Yu-Tzu Tai; Diana Cirstea; Noopur S. Raje; Christoph Uherek; Benjamin Dälken; Silke Aigner; Frank Osterroth; Nikhil Munshi; Paul Richardson; Kenneth C. Anderson
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Rudi Bao; Cheng-Jung Lai; Hui Qu; Dagong Wang; Ling Yin; Brian Zifcak; Ruzanna Atoyan; Jing Wang; Maria Samson; Jeffrey Forrester; Steven DellaRocca; Guang-Xin Xu; Xu Tao; Hai-Xiao Zhai; Xiong Cai; Changgeng Qian
Targeting GIPC/Synectin in Pancreatic Cancer Inhibits Tumor Growth
Michael H. Muders; Pawan K. Vohra; Shamit K. Dutta; Enfeng Wang; Yasuhiro Ikeda; Ling Wang; D. Gomika Udugamasooriya; Adnan Memic; Chamila N. Rupashinghe; Gustavo B. Baretton; Daniela E. Aust; Silke Langer; Kaustubh Datta; Michael Simons; Mark R. Spaller; Debabrata Mukhopadhyay
Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration
Anthony L. Schwartz; Ramiro Malgor; Eric Dickerson; Ashani T. Weeraratna; Andrzej Slominski; Jacobo Wortsman; Norikazu Harii; Aimee D. Kohn; Randall T. Moon; Frank L. Schwartz; Douglas J. Goetz; Leonard D. Kohn; Kelly D. McCall
Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer
Kellie Matthews; Patricia E. Noker; Baohong Tian; Sheila D. Grimes; Ronna Fulton; Karen Schweikart; Raymond Harris; Rose Aurigemma; Minghui Wang; Mack N. Barnes; Gene P. Siegal; Akseli Hemminki; Kurt Zinn; David T. Curiel; Ronald D. Alvarez
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao; Wei Zhou; Si Tuen Lee-Hoeflich; Tom Truong; Peter M. Haverty; Jeffrey Eastham-Anderson; Nicholas Lewin-Koh; Bert Gunter; Marcia Belvin; Lesley J. Murray; Lori S. Friedman; Mark X. Sliwkowski; Klaus P. Hoeflich
Imaging, Diagnosis, Prognosis
A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide
Sharon A. Glynn; Brenda J. Boersma; Tiffany M. Howe; Hege Edvardsen; Stephanie B. Geisler; Julie E. Goodman; Lisa A. Ridnour; Per E. Lønning; Anne-Lise Børresen-Dale; Bjorn Naume; Vessela N. Kristensen; Stephen J. Chanock; David A. Wink; Stefan Ambs
Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
Salvatore Romeo; Maria Debiec-Rychter; Martine Van Glabbeke; Heidi Van Paassen; Paola Comite; Ronald Van Eijk; Jan Oosting; Jaap Verweij; Philippe Terrier; Ulrike Schneider; Raf Sciot; Jean Yves Blay; Pancras C.W. Hogendoorn; on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Cancer Therapy: Clinical
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Sanjay Goel; Alain C. Mita; Monica Mita; Eric K. Rowinsky; Quincy S. Chu; Nancy Wong; Christopher Desjardins; Fang Fang; Mendel Jansen; Dale E. Shuster; Sridhar Mani; Chris H. Takimoto
Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers
Tomonori Tanei; Koji Morimoto; Kenzo Shimazu; Seung Jin Kim; Yoshio Tanji; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Susceptibility and Prevention
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.